The Department of Veterans Affairs formally rescinded its controversial “Evaluative Rating: Impact of Medication” interim final rule on February 27, 2026 — just ten days after publishing it. The rescission took effect immediately upon publication in the Federal Register (91 Fed. Reg. 9712; FR Doc. 2026-03940; Docket No. VA-2026-VBA-0067; RIN 2900-AS49), restoring the prior text of 38 CFR §4.10 and closing out one of the fastest regulatory reversals in VA history.
The original rule — signed by VA Secretary Douglas A. Collins on February 11 and published February 17 — would have required C&P examiners to rate veterans based on how their condition presents while on medication or treatment, not at baseline severity. In plain terms: if your blood pressure medication controlled your hypertension, if your PTSD medication reduced your symptoms, if your pain management helped your back injury, your rating would have reflected that managed state rather than your actual underlying condition.
What the Rescinded Rule Would Have Done
Two key sentences were added to 38 CFR §4.10 — and are now stripped from the regulation entirely. They read: “The medical examiner ‘will not estimate or discount improvements to the disability due to the effects of medication or treatment, whether or not medication or treatment is included within specific rating criteria. If medication or other treatment lowers the level of disability, the rating will be based on that lowered disability level.'”
VA classified the rule as a major rule with $100 million or more in annual economic impact, potentially touching over 350,000 pending claims across more than 500 diagnostic codes. It bypassed the standard public comment period entirely, citing emergency rulemaking authority under 5 U.S.C. 553(b)(B).
The rule directly reversed the legal standard established by the U.S. Court of Appeals for Veterans Claims in Ingram v. Collins, 38 Vet. App. 130 (2025) — a ruling that required VA to discount medication effects when evaluating disability severity in musculoskeletal conditions. That protection had been rooted in earlier precedent including Jones v. Shinseki, 26 Vet. App. 56 (2012), and the concern was that Ingram could be applied broadly across all diagnostic codes, though that broader application remained unresolved.
The Pushback Was Immediate and Bipartisan
The blowback came fast. Within 48 hours of publication, the American Legion, VFW, DAV, IAVA, Burn Pits 360, and Paralyzed Veterans of America had all publicly rebuked the rule. By February 25, Senator Blumenthal noted more than 18,000 public comments had been submitted — nearly all in opposition — with the total count on Regulations.gov ultimately reaching 20,880.
“No veteran should ever have to worry that taking the medicines they need to manage their illnesses and injuries could result in the reduction of their benefits.” — DAV, on the rescission
On February 18, MilVet Law Firm (Tacoma, WA), Stone Rose Law (through attorney Derek Debus), and named plaintiff Andrew Laffoon — a disabled Vietnam veteran — filed a legal challenge in the U.S. Court of Appeals for the Federal Circuit on behalf of more than 500 veterans with pending claims. Lead attorney Paul Jennings — a disabled veteran himself — argued the rule created “a perverse incentive for veterans to skip treatment to protect their benefits.” Secretary Collins announced enforcement was halted by February 19. By February 24, he had signed the rescission document.
“VA always takes Veterans’ concerns seriously and recognizes that many commenters construed the interim final rule as something that could result in adverse consequences.” — VA Official Rescission Statement, Federal Register
On March 30, 2026, the U.S. Court of Appeals for the Federal Circuit formally dismissed Ingram v. Collins, Docket 25-1972, after DOJ and VA abandoned their appeal. Ingram is now settled law. VA must evaluate disability severity at baseline, independent of medication effects.
Who Is Affected and What You Need to Know
If you have an established disability rating, nothing changed — your rating was never at risk from this rule. Ratings in place for 20 or more years carry additional protection under 38 CFR §3.951(b).
If you have a pending claim or a request for increased rating, your claim will be adjudicated under the restored standard. Examiners must evaluate your condition at its underlying severity, not through the lens of how well your prescriptions are managing it.
If your C&P exam occurred between February 17 and February 27, 2026 — the ten days the rule was technically in force — watch your rating decision carefully. If your examiner appeared to factor in medication-controlled symptom improvement as the basis for a lower rating, that could be grounds for a supplemental claim or appeal. Contact a VA-accredited attorney or a VSO immediately.
What to Watch Next
The underlying legal question about how broadly Ingram applies across all diagnostic codes — not just musculoskeletal conditions — is still being worked through the claims system. VA has pledged greater stakeholder communication before any future regulatory changes of this magnitude. For questions about the rescission rule, VA’s contact is Ethan Kalett, Executive Director, Office of Regulatory Oversight and Management, at (202) 461-9700.
Leave a Reply